Results 181 to 190 of about 13,748 (197)

NTRK‐rearranged mesenchymal tumour with epithelioid features: expanding the morphological spectrum of NTRK‐fused neoplasms

Histopathology, 2021
Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive neoplasms were first identified in colorectal carcinoma almost 40 years ago1 . The availability of tyrosine kinase inhibitors specifically targeting receptors encoded by NTRK genes (Trk receptors), together with a considerable clinical response and favourable safety profile has sparked ...
João Victor Alves de Castro, Felipe D’Almeida Costa, Giovana Tardin Torrezan, Dirce Maria Carraro, Ulisses Ribaldo Nicolau, Antônio Geraldo do Nascimento   +5 more
openaire   +2 more sources

EU-Zulassung für NTRK-Inhibitor

InFo Hämatologie + Onkologie, 2019
Die EU-Kommission hat fur den NTRC-Inhibitor Larotrectinib erstmals eine vollstandig tumoragnostische Zulassung ausgesprochen.
openaire   +1 more source

Larotrectinib bei Lungenkrebs und NTRK-Genfusion

Onkologische Welt, 2021
Aktualisierte Daten einer Kohorte von erwachsenen Patienten mit NTRK (a)-Genfusions-positivem Lungenkrebs, die mit Larotrectinib (Vitrakvi®) behandelt wurden, zeigten eine Gesamtansprechrate (ORR) von 71 % (n = 14). Die Patienten hatten im Median 3 Vortherapien (Bereich 0–5) erhalten.
openaire   +1 more source

Myxoid Spindle Cell Sarcoma With LMNA-NTRK Fusion: Expanding the Morphologic Spectrum of NTRK-Rearranged Tumors

International Journal of Surgical Pathology, 2020
Neurotrophic tyrosine receptor kinase ( NTRK)-rearranged spindle cell neoplasm is a recently described soft tissue tumor entity that occurs predominantly in children and young adults. The diagnosis of this tumor is difficult due to the nonspecific and highly variable morphology, yet it is of clinical relevance because of the availability of highly ...
Yik Ka So, Chit Chow, Ka Fai To, John K. C. Chan, W. Cheuk   +4 more
openaire   +2 more sources

BPI21-006: Timing of NTRK Gene Fusion Testing and Treatment Modifications Following NTRK+ Status Among U.S. Oncologists Treating NTRK+ Patients

Journal of the National Comprehensive Cancer Network, 2021
Landon Z. Marshall, Andrew J. Klink, Abhishek Kavati, Ruth Antoine, Sibyl Anderson, Bruce Feinberg   +5 more
openaire   +1 more source

Cost-effectiveness of NTRK testing strategies for detecting NTRK fusions in solid tumors in China.

Journal of Clinical Oncology
3131 Background: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in many solid tumors. With the inclusion of the targeted drug Entrectinib in China's national reimbursement drug list, the demand for NTRK testing has also increased.
Jian Wang, Lifeng Wang, Shenglei Li, Wen Chen   +3 more
openaire   +1 more source

NTRK-Targeted Therapy in Lung Cancer

2019
Gene rearrangements or fusions as a tumorigenic genomic driver event have been identified as a common recurrent occurrence in a variety of human malignancies. The neurotrophic tyrosine receptor kinase gene family contains NTRK1, NTRK2, and NTRK3, which encode the proteins tropomyosin receptor kinase A, B, and C (TRKA, TRKB, TRKC), respectively.
Xiaoliang Wu, Lin Zhu, Patrick C. Ma
openaire   +1 more source

173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2

Annals of Oncology, 2022
J. Lu, C.M. Blakely, M. Barve, C.H. Chung, S.N. Waqar, X. Hu, J-P. Delord, M.J. Krzakowski, K. Yonemori, D.T. Chen, D. Klingbiel, S. Heinzmann, C. Le Tourneau   +12 more
openaire   +1 more source

NTRK-rearranged soft tissue neoplasm

2022
Joachim Feger, Arlene Campos
openaire   +1 more source

Zielstruktur NTRK-Genfusionen

Im Focus Onkologie, 2018
openaire   +1 more source